Aelisfarma.com
WebApr 12, 2024 · Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug …
Aelisfarma.com
Did you know?
Web1 day ago · Aelis Farma is specialized in the research and development of drugs for the treatment of major disorders of the Central Nervous System (CNS). The company has 2 products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis and acute toxicity), and AEF0217 for cognitive deficits … WebJan 17, 2024 · BORDEAUX, France-- ( BUSINESS WIRE )-- Aelis Farma (the “Company”), a clinical-stage biopharmaceutical company specializing in the development of treatments …
WebAELIS Share Price $15.09 (As of Friday Closing) General Information Description Aelis Farma SA is a biotechnology company specialized in the treatment of brain disorders. … WebMay 26, 2016 · Electronic address: [email protected]. PMID: 25967266 DOI: 10.1016/j.neuroscience.2015.05.002 Research Support, Non-U.S. Gov't Review Animals Astrocytes / metabolism* Brain / metabolism Humans Memory, Short-Term / physiology Neuronal Plasticity / physiology Neurons / metabolism* Receptor, Cannabinoid, CB1 / …
WebFounded in 2013 Private Company "Aelis Farma is develop the therapeutic potential of CB1-SSi (CB1 Signaling Specific inhibitors). CB1 Signaling Specific inhibitors are a proprietary new pharmacological class never tested in humans before that open a … WebVoir le profil de Pier Vincenzo Piazza sur LinkedIn, le plus grand réseau professionnel mondial. Pier Vincenzo a 2 postes sur son profil. Consultez le profil complet sur LinkedIn …
WebFeb 2, 2024 · To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or create an account.
WebVoir le profil de Stéphanie Monlezun sur LinkedIn, le plus grand réseau professionnel mondial. Stéphanie a 3 postes sur son profil. Consultez le profil complet sur LinkedIn et découvrez les relations de Stéphanie, ainsi que des emplois dans des entreprises similaires. herbs that go with eggsWebContact Email [email protected] Phone Number +33 5 57 57 37 70 Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and … matters related to fastingWebAelis Farma annonce son calendrier financier pour l’exercice 2024 • Boursorama CP 16 déc. 2024 AELIS FARMA annonce le recrutement du premier patient de l’étude clinique de phase 1/2 avec son... matters requiring attention occWebAelis Farma’s Mission ” To combine the scientific breakthrough of CB 1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet … Meet Us - Home - AelisFarma Signaling Specific inhibitors of the cannabinoid type 1 receptor (CB 1-SSi) … Pipeline - Home - AelisFarma Partners - Home - AelisFarma [email protected]. Send us a message. Your name. Your email. … [email protected]. NewCap. Financial communication & … matters relating to assessment complaintsWebMar 30, 2024 · Founded in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi).... matters required attentionWebApr 26, 2024 · It can be consulted on the Company's website at www.aelisfarma.com. About AELIS FARMA. Founded in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the ... matters rhyming wordsWebaelisfarma.com. CEO. Pier Vincenzo Piazza. Headquarters. Bordeaux. Employees. 20. Founded. 2013. Aelis Farma SA develops biotechnology solutions. It offers therapeutic … matters requiring board attention fdic